pharma · Hepatocellular Carcinoma · Hepatocellular Carcinoma (HCC) · TPST
Tempest Therapeutics
Tempest Therapeutics is a pharma organization headquartered in Brisbane, USA. It trades on NYSE under ticker TPST. Primary therapeutic focus areas include Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC), Solid T
Brisbane, USA HQ
14 Employees
Public company Type
TPST · NYSE Ticker
Company details
- Status
- Public
- HQ
- Brisbane, USA
- Employees
- 14
- Programs
- 0
- Drugs
- 1
- Patents
- 0
TPST-1120
Phase 3 · small molecule · Hepatocellular Carcinoma (HCC)
TPST-1120 for Hepatocellular Carcinoma (HCC) is a Phase 3 program (small_molecule) at Tempest Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code TPST-1120-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Tempest Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Hepatocellular Carcinoma (HCC)
- Status
- active
- Trials
- 1